Caribou Biosciences

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Mr. Johnson brings 30 years of commercial experience to Caribou as company's pipeline of genome-edited cell therapies advances -- -- Mr. Johnson brings 30 years of commercial experience to Caribou as company's pipeline of genome-edited cell therapies advances --

Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors

-- Initial ANTLER Phase 1 clinical data scheduled to be shared at the European Hematology Association (EHA) 2022 Hybrid Congress for CB-010, the Company's lead allogeneic cell therapy candidate, in patients with r/r B-NHL -- -- Submission of IND application planned in H2 2022 for CB-011, Caribou's second allogeneic cell therapy candidate, for evaluation in patients with r/r multiple myeloma --

Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates

BERKELEY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will participate in a fireside chat at the following upcoming investor conference in May:

Caribou Biosciences to Present at Upcoming Investor Conference

-- Data highlight the mechanism underlying the superior specificity of Caribou's chRDNA genome-editing technology in primary human T cells -- -- Data highlight the mechanism underlying the superior specificity of Caribou's chRDNA genome-editing technology in primary human T cells --

Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)

-- Abstract accepted on initial clinical data from the ANTLER Phase 1 trial of CB-010, Caribou's lead allogeneic cell therapy for patients with r/r B-NHL -- -- Abstract accepted on initial clinical data from the ANTLER Phase 1 trial of CB-010, Caribou's lead allogeneic cell therapy for patients with r/r B-NHL --

Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress

-- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked  to blunt both T- and NK-mediated immune cell rejection,  enabling more durable antitumor activity -- -- Data support an expected Investigational New Drug (IND) application submission in 2022 for  CB-011, Caribou's second allogeneic cell therapy product candidate --

Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting

-- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate  for patients with r/r B-NHL -- -- 2022 submission of IND application planned for CB-011, an allogeneic cell therapy candidate for patients with r/r multiple myeloma --

Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

BERKELEY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinical data from CB-011, its allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma (r/r MM), will be presented as a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022 in New Orleans.

Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

BERKELEY, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will present a company overview at the following upcoming investor conferences in March:

Caribou Biosciences to Present at Upcoming Investor Conferences

BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17th, at 2:20 pm ET.

Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Dr. Rizvi brings significant experience in oncology cell therapy development Dr. Rizvi brings significant experience in oncology cell therapy development

Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer

BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 am ET.

Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

The shares of Caribou Biosciences Inc (NASDAQ: CRBU) have received a $28 price target from H.C. Wainwright.

Caribou Biosciences (CRBU) Stock: $28 Price Target From H.C. Wainwright

On track to achieve key milestones, including plan to disclose initial clinical data in 2022 for lead product candidate CB-010

Caribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results

BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has appointed Ran Zheng to its board of directors. Ms. Zheng brings over 25 years of biotechnology industry leadership experience in biologics drug development with broad expertise in technical operations and the manufacture of gene and cell therapies.

Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors

BERKELEY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will participate in a fireside chat on Monday, October 4, 2021, at 5:00 pm ET at the Chardan Virtual 5th Annual Genetic Medicines Conference. Dr. Haurwitz will also be part of a panel discussion: “Gene Editing: Next-Generation Technologies Worth Watching” on Tuesday, October 5, 2021, at 12:00pm ET.

Caribou Biosciences to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou's proprietary chRDNA technology for therapeutic applications

Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology

Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters' option to purchase additional shares

Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results

BERKELEY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appointed Nancy Whiting, Pharm.D., to its board of directors. Dr. Whiting brings over 17 years of biotechnology industry expertise in drug and portfolio development, as well as significant strategic leadership experience.

Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors

BERKELEY, Calif.--(BUSINESS WIRE)---- $CRBU--Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previously announced initial public offering of 19,000,000 shares of common stock, at a price to the public of $16.00 per share. In addition, Caribou has granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less the under

Caribou Biosciences Announces Closing of Upsized Initial Public Offering

The company has a pedigree and a novel approach that could put it at the top of the CRISPR heap.

3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering of 19,000,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Caribou. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Caribou, are ex

Caribou Biosciences Announces Pricing of Upsized Initial Public Offering

Caribou Biosciences has filed proposed terms for a $255 million IPO. The firm is developing hybrid CRISPR-Cas9-derived gene therapies for various cancers.

Caribou Biosciences Aims For $255 Million IPO

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that the first patient has been dosed in its open-label, multicenter ANTLER phase 1 clinical trial (NCT04637763) to evaluate the company's lead product candidate, CB-010, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells that ha

Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Co-founded in 2011 by Jennifer Doudna, 2020 Nobel prize winner in Chemistry. Caribou offers licenses to its CRISPR-Cas9 foundational IP in multiple fields.

News for Caribou Biosciences Stock (CRBU)